I'm not sure if your onco is saying there are no studies on Orgovyx+abiraterone, or Lupron+abiraterone, but it should not matter. All of these patients being put on ADT + abiraterone/Zytiga with high risk localized or locally advanced disease are doing so based on the STAMPEDE trial that has been ongoing in the UK and Switzerland. One of the many trials included under STAMPEDE was for patients with high risk, non-metastatic disease. It did include patients with locally advanced disease , i.e., pelvic nodes. The latest reporting I saw was at 108 months from start of treatment PCa-specific survival was 85-ish% for the arm in which patients took abiraterone in addition to ADT and high 60's% in the arm with ADT only. That is a huge benefit and is what caused the standards bodies to designate this combination therapy for high risk, non-metastatic patients as Standard of Care. There was no distinction made by the type of ADT used in both arms, so Lupron versus Orgovyx should be a non-issue.

So I would press your doctor to show you proof there is no evidence of that combination being used. It has been Standard of Care for some time now. Mention the STAMPEDE trial.